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Cerebral vasospasm (CV) remains the leading cause of delayed morbidity and mortality following aneurysmal subarachnoid
hemorrhage (SAH). However, increasing evidence supports etiologies of delayed cerebral ischemia (DCI) other than CV. Estrogen,
specifically 17𝛽-estradiol (E2), has potential therapeutic implications for ameliorating the delayed neurological deterioration
which follows aneurysmal SAH. We review the causes of CV and DCI and examine the evidence for E2-mediated vasodilation
and neuroprotection. E2 potentiates vasodilation by activating endothelial nitric oxide synthase (eNOS), preventing increased
inducible NOS (iNOS) activity caused by SAH, and decreasing endothelin-1 production. E2 provides neuroprotection by increasing
thioredoxin expression, decreasing c-Jun N-terminal kinase activity, increasing neuroglobin levels, preventing SAH-induced
suppression of the Akt signaling pathway, and upregulating the expression of adenosine A2a receptor. The net effect of E2
modulation of these various effectors is the promotion of neuronal survival, inhibition of apoptosis, and decreased oxidative damage
and inflammation. E2 is a potentially potent therapeutic tool for improving outcomes related to post-SAH CV and DCI. However,
clinical evidence supporting its benefits remains lacking. Given the promising preclinical data available, further studies utilizing E2
for the treatment of patients with ruptured intracranial aneurysms appear warranted.
1. Introduction
Spontaneous subarachnoid hemorrhage (SAH) secondary
to rupture of intracranial aneurysms represents a relatively
small fraction of strokes (5%). However, the morbidity and
mortality associatedwith aneurysm rupture remain very high
despite advances in the diagnosis and treatment of aneurys-
mal SAH [1]. Cerebral vasospasm (CV) is the leading cause
of delayed morbidity and mortality following aneurysmal
subarachnoid hemorrhage (SAH). While radiographic CV is
present in up to 70% of SAH patients, clinically symptomatic
CV occurs in only 20–30% [2]. However, it is now evident
that CV alone is inadequate to completely explain the delayed
neurological dysfunction which occurs in the one to two
weeks following the ictus of aneurysm rupture [3, 4].
After the age of 40, aneurysmal SAH is more common
in females [5, 6]. The typical age of menopause, when serum
estrogen levels decrease dramatically, is approximately 50
years [7]. It remains controversial whether the temporal
relationship between decreased estrogen levels and increased
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incidence of aneurysm rupture in women is causative [8].
Despite extensive research on the effect of estrogen on
aneurysm formation, progression, and rupture, the efficacy
of estrogen for the treatment of SAH-induced CV has not
been well investigated. With this deficiency in mind, we
review the pathogenesis of aneurysmal SAH-induced CV,
delayed cerebral ischemia (DCI), and the potential role
of estrogen, specifically 17𝛽-estradiol (E2), in combating
these two interrelated but distinct cerebrovascular disease
processes.
2. Pathogenesis of Aneurysmal Subarachnoid
Hemorrhage-Induced Cerebral Vasospasm
2.1. Smooth Muscle Cell Contractile Mechanisms. In order to
properly understand the molecular mechanisms of CV, we
first briefly describe the manner by which smooth muscle
cells (SMC) in themedia of cerebral vasculature regulate con-
traction and relaxation [9]. The process of SMC contraction
begins with opening of voltage-gated or ligand-gated calcium
(Ca) channels allowing the entry of Ca from the extracellular
space and from within the sarcoplasmic reticulum into the
cytoplasm. The binding of cytoplasmic Ca to calmodulin
(CaM), forming the Ca-CaM complex, can then activate the
enzyme myosin light chain kinase (MLCK) to phosphorylate
myosin. Phosphorylation of myosin allows it to bind to actin.
At a cellular level, the coupling of myosin to actin results in
SMC contraction which translates to vasoconstriction at the
physiologic level.
2.2.Mechanisms of Cerebral Vasospasm Secondary to Endothe-
lial Injury. Endothelial dysfunction is one of the primary
contributing factors to CV following aneurysmal SAH.
Endothelins (ET) are the most potent endogenous activators
of vasoconstriction. ETs are produced by the endothelium
and play a key role in maintaining vascular homeostasis.
In the setting of SAH, the cerebrospinal fluid (CSF) levels
of ET-1, the most common ET isoform, have been shown
to be increased [10]. ET-1 binds to the endothelin recep-
tor of which the two best characterized and most studied
isoforms are ETA and ETB [11]. Binding of ET-1 to ETA
and ETB results in vasoconstriction via pathways mediated
by protein kinase C (PKC) [12]. PKC, which is activated
by diacylglycerol (DAG) generated by phospholipase C and
Ca generated from the opening of inositol triphosphate
(IP3) gated Ca channels in the sarcoplasmic reticulum,
promotes further Ca influx by opening cell surface Ca chan-
nels. In addition to Ca-dependent vasoconstriction, PKC
also mediates Ca-independent vasoconstriction and vascular
remodeling via mitogen-activated protein kinase (MAPK)
[13].
Nitric oxide (NO), also known as endothelium-derived
relaxing factor, is produced from arginine by the enzyme
nitric oxide synthase (NOS) which exists in constitutively
expressed isoforms, endothelial NOS (eNOS), neuronal NOS
(nNOS), and the inducible isoform iNOS [14]. NO induces
SMC relaxation increasing intracellular levels of the second
messenger cyclic guanine monophosphate (cGMP) via acti-
vation of guanylate cyclase. The mechanisms by which ele-
vated cGMP levels promote vasodilation include prevention
of SMC depolarization by inhibition of Ca influx, facilitation
of SMC hyperpolarization by activation of potassium (K)
channels, and inhibition of SMC contraction by dephos-
phorylation of myosin by myosin light chain phosphatase
(MLCP) which is activated by a cGMP-dependent kinase
[15]. Decreased availability of NO secondary to hemoglobin-
mediated destruction of nNOS and endogenous asymmetric
dimethylarginine (ADMA)mediated inhibition of eNOS also
contributes to the development of CV [16].
2.3. Mechanisms of Cerebral Vasospasm Secondary to Inflam-
mation and Smooth Muscle Cell Injury. Acute subarachnoid
hemorrhage generates the product oxyhemoglobin (oxy-Hb)
which results in vasoconstriction via generation of reactive
oxygen species (ROS) such as superoxide and hydrogen
peroxide [17]. These ROS scavenge NO thereby prevent-
ing vasodilation. Upregulation of Ca channels by oxy-Hb
may increase the sensitivity of the cerebral vasculature to
contractile stimuli and both prolong and potentiate vaso-
constriction [18]. Furthermore, oxy-Hb also results in an
inflammatory cascade in the walls of the cerebral ves-
sels. Inflammation activates iNOS which, in contrast to its
constitutively active counterparts, causes cellular damage
by generation of NO in an oxidative environment which
then reacts with free radicals to propagate ROS formation.
The elevation of ROS levels by iNOS results in further
local vascular inflammation. Activation of the inflammatory
cascade is induced at the ictus of SAH and contributes
to the subsequent development of CV. In an experimental
SAH model in primates, infiltration of inflammatory cells
into the walls of cerebral vessels was shown to be the
highest, one week following SAH induction, which cor-
related with the peak severity of angiographic vasospasm
[19].
Proteins which promote cell-cell interactions have been
shown to be upregulated during the inflammatory response
in order to facilitate the recruitment, adhesion, and transmi-
gration of leukocytes [20]. Intercellular adhesion molecule-1
(ICAM-1) is a ligand for the receptor lymphocyte function-
associated antigen-1 (LFA-1) which is ubiquitously expressed
not only on all T-cells but also on other immune cells such
as neutrophils, macrophages, and B-cells. The coupling of
ICAM-1 to LFA-1 is a crucial initial step to the recruitment of
inflammatory cells to the vessel wall. Increased expression of
ICAM-1 has been demonstrated in endothelial cells following
exposure of the adventitia to blood [21]. Aihara et al. [22]
measured the level and evaluated the time course of cytokine
and cell adhesion molecule gene expression following induc-
tion of SAH in canines. They determined that the peak
expression of interleukin-1 (IL-1), IL-6, IL-8, and ICAM-1
was seven days after SAH which correlated with maximal
arterial narrowing on angiography. These results implicate
a prolonged inflammatory response in CV with a potential
correlation between the magnitude of inflammation and the
severity of vasoconstriction.
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In addition to ICAM-1, other cell adhesion molecules,
such as vascular cell adhesion molecule-1 (VCAM-1) and E-
selectin, have shown to be increased in the CSF of patients
following aneurysm rupture [23]. Nissen et al. [24] studied
the serum levels of multiple cell adhesion molecules in
aneurysmal SAH patients with and without delayed ischemic
neurological deficit (DIND) and did not find differences
in the levels of ICAM-1, VCAM-1, platelet endothelial cell
adhesion molecule-1 (PECAM-1), or E-selectin between the
two cohorts. The levels of P-selectin and L-selectin were
significantly higher and lower, respectively, in the patients
who developed DIND. While there is clearly a link between
inflammation and CV, it is clear that the use of CSF and
serum biomarkers to assess this correlation is imperfect.
Refinement of current approaches or development of new
biomarker assays is necessary before these approaches can
achieve widespread clinical applicability.
SMC contractility is not only mediated by SAH-induced
variations in ET-1 and NO levels, but also by alteration
in the electrochemical balance of ions such as Ca, sodium
(Na), potassium (K), and chloride (Cl). SAH causes SMC
depolarization by activation of Ca and Na channels and
inactivation of K channels. Nimodipine, a Ca channel blocker
(CCB), is the only pharmacologic agent which has been
clinically proven to reduce delayed morbidity and mortality
from aneurysmal SAH, although it does not reduce the
incidence of angiographic CV [25–27]. The clinical benefit
of endovascular administration of intra-arterial CCBs, such
as verapamil, is currently equivocal [28]. The K channel acti-
vator cromakalim has been shown, in an in vivo rabbit SAH
model, to ameliorate vasospasm [29]. Pathological alterations
in ion channel physiology are crucialmechanisms underlying
the molecular and clinical manifestations of CV. However,
artificial manipulation of ion balance alone is inadequate to
prevent or reverse the disease process.
Additional evidence suggests that SMC contractile tone
and the mechanisms which regulate SMC contraction may
change over the time course of CV [30]. This suggests
that changes in SMC physiology may be induced by SAH.
While the role of SMC phenotypic modulation in aneurysm
formation, progression, and rupture has been studied, its
role in the inflammation associated with CV is currently
unknown [31]. A recent study by Kim et al. [32] identified
a single nucleotide polymorphism in the gene encoding the
NaCl cotransporter SLC12A3. Despite extensive research into
themolecular biology and biochemistry of aneurysmal SAH-
induced CV, the mechanisms underlying its pathogenesis
remain incompletely understood.
3. Pathogenesis of Aneurysmal Subarachnoid
Hemorrhage-Induced Delayed Cerebral
Ischemia Unrelated to Cerebral Vasospasm
DCI unrelated to CV is becoming increasingly recognized as
a significant contributor to delayed morbidity in aneurysmal
SAH patients. These non-CV sources of neurological dys-
function may provide an explanation for the continuing fail-
ures of clinical trials using pharmacological inhibitors which
target CV [33, 34]. In addition to cerebral ischemia secondary
to lack of blood supply in the setting of CV-induced vaso-
constriction, global DCI occurs following SAH secondary
to activation of proapoptotic pathways [35]. The initiation
of proapoptotic mechanisms likely occurs with the acute
brain injury which accompanies the ictus of SAH. The rapid
increase in intracranial pressure cannot be compensated for
by higher levels of cerebral blood flow thereby resulting in a
decrease in cerebral perfusion pressure (CPP). This sudden
drop in CPP activates the stress response transcriptional
regulatory protein hypoxia-inducible factor 1𝛼 (HIF-1𝛼) [36].
HIF-1𝛼 increases the production of BCL2/adenovirus E1B
19 kDa protein-interacting protein (BNIP3) which promotes
apoptosis by releasing cytochrome c from the mitochondria.
This subsequently activates downstream caspases and by
sequestering the antiapoptotic protein Bcl-2.
In addition to modulation of apoptotic pathways, SAH
also causes disruption of the blood-brain barrier (BBB)
by activation of matrix metalloproteinases (MMPs) which
degrade the vascular basement membrane [37, 38]. Park et al.
[39] observed increased BBB permeability, increased cerebral
edema, and apoptosis of endothelial cells and hippocampal
and cortical neurons after SAH induction in rats. Adminis-
tration of a pan-caspase inhibitor reduced BBB permeability,
prevented development of cerebral edema, and improved
neurological outcome. The integrity of the BBB is not only
important in limiting the accumulation of cerebral edema,
but it is also linked to the prevention of proinflammatory
signals and neuronal apoptosis [40]. Another cerebrovascular
alteration following SAH is the dysfunction of the micro-
circulation. Rather than vasoconstriction of large arteries,
some studies have suggested that the narrowing of small
parenchymal arterioles contributes to pathological alterations
in regional cerebral blood flow and to the development of
DCI [41, 42].
Microvascular platelet aggregation following SAH is
another potential mechanism which may mediate DCI sec-
ondary to small vessel thrombosis and cortical and subcorti-
cal ischemia. Sehba et al. [43] detected microvascular platelet
aggregation in SAH-induced rats by immunostaining for the
glycoprotein IIb/IIIa (GPIIb/IIIa), the receptor on activated
platelets responsible for mediating fibrin cross-linking. An
autopsy study of 29 patients who died from aneurysm rup-
ture identified a statistically significant correlation between
the magnitude of microvascular thromboembolism burden,
detected by immunostaining, and the histologic evidence of
ischemia at autopsy as well as clinical evidence of DCI prior
to death [44].
In addition to microcirculatory disease, widespread cor-
tical depression may predispose SAH patients to DCI. Dreier
et al. [45] performed electrocorticography on patients who
were surgically treated for ruptured aneurysms and found
spreading depolarizations in 72%. The electrocorticographic
measurement of recurrent spreading depolarizations had
86% and 100%positive and negative predictive values, respec-
tively, for the development of delayed ischemic neurologi-
cal deficits. The authors proposed that repeated spreading
depolarizations with prolonged depressions could predict
the subsequent occurrence of DCI. It is likely that many of
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the aforementioned pathologicalmechanisms are interrelated
with the development, propagation, and worsening of CV
[46]. However, past clinical outcomes from aneurysmal SAH
studies have taught us that the reversal of angiographic
CV alone is inadequate to ameliorate the delayed morbidity
and mortality associated with the rupture of an intracranial
aneurysm.
4. Role of Estrogen in the Treatment of
Cerebral Vasospasm
4.1. Estrogen Physiology. E2 is the most potent endogenous
estrogen. Like other steroid hormones, E2 is derived
from cholesterol. Cholesterol is initially converted to the
intermediate progesterone products, pregnenolone and
17𝛼-hydroxypregnenolone, which are then converted to
the androgen intermediates, dehydroepiandrosterone,
androstenediol, androstenedione, and testosterone. The
androgen testosterone is then converted by the final enzyme
in the synthetic pathway, aromatase, into E2. In a parallel
pathway, androstenedione is converted by aromatase into
estrone (E1) which, in vivo, is interconvertible with E2 [47].
E2 passes through the cell membrane to bind to the two
isoforms of the estrogen receptor (ER), ER𝛼 and ER𝛽, in
the cytoplasm. The E2-ER complex then enters the cell
nucleus to regulate the transcription of multiple genes [48].
Pharmacologic blockade of the physiologic effects of E2
targets the synthetic pathway or the receptor. E2 synthesis
is decreased with gonadotropin-releasing hormone (GnRH)
agonists (e.g., leuprolide, goserelin) and aromatase inhibitors
(e.g., anastrozole, exemestane). Antagonists of the ER are
more properly termed selective estrogen receptormodulators
(SERM) since, rather than being pure antagonists, they are
simultaneously partial agonists as well as antagonists [49].
The action of SERMs is tissue specific and varies depending
on the relative ratio of coactivator to corepressors and on the
conformation of the ER.
4.2. Effect of Estrogen on the Vasculature during Cerebral
Vasospasm. E2 is a powerful vasodilator with the potential
to prevent or reverse the vasoconstriction which occurs
in CV. In vitro studies have demonstrated that E2 binding
to ER𝛼 results in activation of eNOS through MAPK-
dependent pathways [50]. In vivo evidence from continuous
E2 treatment of SAH-induced animals showed attenuation of
CV, decreased SAH-induced iNOS expression, and normal
eNOS expression [51]. This implicates a dual role of E2 in
the prevention of SAH-induced iNOS upregulation and the
maintenance of normal eNOS activity (which is typically
suppressed in the setting of SAH). Mechanistic data from in
vitro studies by Zancan et al. [52] demonstrated abrogation
of cytokine-induced iNOS upregulation by E2 treatment in
cultured rat aortic SMCs. Blockade of E2 signaling with an
ER𝛼 antagonist resulted in the absence of E2 modulation of
iNOS expression.
Shih et al. [53] treated SAH-induced rats with E2 and a
nonselective ER antagonist and found that E2 prevented post-








Figure 1: Pathways of E2-mediated facilitation of vasodilation and
inhibition of vasoconstriction. E2: 17𝛽-estradiol, eNOS: endothelial
nitric oxide synthase, ET-1: endothelin-1, iNOS: inducible nitric
oxide synthase, NO: nitric oxide, and ROS: reactive oxygen species.
mechanism. The study also examined the levels of p65, a
subunit of nuclear factor 𝜅 light chain enhancer of activated B
cells (NF𝜅B) and identified increased association of p65 and
ER following administration of E2.The nuclear translocation
of p65 was unaffected by E2 treatment. Therefore, a potential
mechanism of E2-mediated vasodilation is the cytoplasmic
sequestration of the transcription factor NF𝜅B by ER which
prevents the NF𝜅B-dependent upregulation of iNOS insti-
gated by aneurysmal SAH. Studies in extracranial vasculature
have suggested that E2 may potentiate the effect of MMPs
on the modulation of ET-mediated vasoconstriction [54].
Additional in vivo data from an experimental SAH model
in rats demonstrated significantly decreased levels of ET-1
production in the cohort treated with E2 [55].The ET-1 levels
of the SAH animals treated with E2 were not significantly
different fromET-1 levels of control animals.Themechanisms
by which E2 mediates vasodilation are depicted in Figure 1.
5. Neuroprotective Mechanisms of
Estrogen in the Setting of Aneurysmal
Subarachnoid Hemorrhage
Evidence suggests that E2 may have neuroprotective proper-
ties [56]. E2 appears to diminish the risk of ischemic stroke
and neurodegenerative disorders, such as Alzheimer’s and
Parkinson’s disease [57]. Not all neuroprotection afforded by
E2 is mediated by ER. Early studies found E2 to have antiox-
idant effects, via scavenging of ROS, which were unaffected
by tamoxifen treatment [58]. Lee et al. [59] showed that E2
increased expression of the antioxidant thioredoxin (Trx) in
a cGMP-dependent manner. Trx was demonstrated, in the
same study, to abrogate lipid peroxidation, caspase-3 activa-
tion, and apoptosis in response to oxidative stress. Srivastava
et al. [60] found that E2 decreased expression of the critical
proinflammatory cytokine tumor necrosis factor 𝛼 (TNF𝛼)
by causing reduced activity of c-JunN-terminal kinase (JNK).
Depression of JNK results in decreased phosphorylation of its


















Figure 2: Pathways of E2-mediated neuroprotection. Akt: protein kinase B, E2: 17𝛽-estradiol, ERK1/2: extracellular signal-regulated kinases
1 and 2, GSK3𝛽: glycogen synthase kinase 3𝛽, JNK: c-Jun N-terminal kinase, mTOR: mammalian target of rapamycin, Ngb: neuroglobin,
TNF𝛼: tumor necrosis factor 𝛼, and Trx: thioredoxin.
downstream targets which heterodimerize to form the tran-
scription factor activator protein-1 (AP-1). AP-1 transactivates
TNF𝛼 by binding to its promoter region. Thus, E2-mediated
disruption of AP-1 formation decreased transcription of
TNF𝛼. Xing et al. [61] subsequently demonstrated that the
anti-inflammatory actions of E2 were dependent on the ER𝛽
receptor isoform. In addition to decreasing TNF𝛼 expression,
E2 binding to ER𝛽 also hindered neutrophil chemotaxis
by decreasing expression of P-selectin, ICAM-1, VCAM-1,
monocyte chemoattractant protein-1 (MCP-1), and cytokine-
induced neutrophils chemoattractant-2𝛽 (CINC-2𝛽).
Neuroglobin (Ngb) is a protein which regulates neuronal
oxygen homeostasis by binding to oxygen with a higher
affinity than hemoglobin [62]. While the precise mechanism
of Ngb has yet to be delineated, it likely contributes to
the protection of the brain from oxidative damage by ROS.
De Marinis et al. [63] found that in vitro treatment of
mouse hippocampal neurons with E2 resulted in a threefold
increase in Ngb levels which was mediated by the ER𝛽
receptor. The ER𝛽-mediated upregulation of Ngb expression
was dependent on the p38 class of MAPKs. Additionally,
E2 afforded protection against apoptosis induced by hydro-
gen peroxide. This protective effect was abrogated in Ngb-
silenced cells. Hota et al. [64] provided in vivo data to support
the antiapoptotic role of Ngb during the neuronal stress
response to hypoxic stimuli. Ngb was shown to stabilize the
transcription factors HIF-1𝛼 and nuclear factor erythroid 2-
related factor 2 (Nrf2) and prevent mitochondrial release of
the caspase-activating protein cytochrome c.
Recent in vivo evidence presented by Kao et al. [65]
implicates the Akt signaling pathway in E2-mediated neuro-
protection. Akt, otherwise termed protein kinase B (PKB),
is downstream from phosphoinositide 3-kinase (PI3K) and
upstream from the kinase known as mammalian target of
rapamycin (mTOR). This complex signaling pathway involv-
ing the three kinases PI3K, Akt, and mTOR, integrates mul-
tiple inputs in order to promote cell growth and proliferation
[66]. Downstream inactivation of glycogen synthase kinase
3𝛽 (GSK3𝛽) by Akt is known to inhibit apoptosis [67].
Activation of ER𝛼 by E2 was shown to inhibit apoptosis in
the dentate gyrus of rats afflicted with SAH by depressing
the activity of the proapoptotic enzyme caspase-3 and by
preventing the SAH-induced decrease in signaling through
Akt [65]. Prior studies potentiating signaling through Akt-
GSK3𝛽 pathway by othermechanisms have also shown atten-
uation of neuronal cell death in the setting of SAH [68, 69].
Furthermore, E2 has been found to exert antiapoptotic effects
through upregulation of adenosine A2a receptor (A2aAR)
and extracellular signal-regulated kinases 1 and 2 (ERK1/2)
expression [70]. The activation of A2aAR and ERK1/2 results
in inhibition of downstream apoptotic signaling pathways.
The mechanisms by which E2 mediates neuroprotection
are depicted in Figure 2. Table 1 summarizes the molecular
mechanisms underlying E2-mediated vasodilation and neu-
roprotection.
6. Limitations of Current Studies and
Future Directions
Estrogen treatment is associated with multiple potential
adverse effects which may dampen the enthusiasm for its
use in the treatment of aneurysmal SAH patients. These
risks include malignancies of the breast, endometrium, and
ovaries, dysmenorrhea, gastrointestinal dysfunction, dyslipi-
demia, venous thrombosis, pulmonary embolism, myocar-
dial infarction, and stroke [71–73]. Due to the relatively
short clinical time course during which estrogen would be
administered to treat CV and DCI (i.e., approximately two
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Table 1: Summary of vasodilatory and neuroprotective mechanisms regulated by 17𝛽-estradiol (E2).
Mediator Physiology
Vasodilatory mechanisms regulated by E2
Endothelial nitric oxide synthase (eNOS)
Constitutively expressed isoform of NOS which generates the
vasodilatory mediator NO. E2 activates eNOS and prevents the
SAH-induced decrease of eNOS function via MAPK-dependent
pathways.
Inducible nitric oxide synthase (iNOS)
Inducible isoform of NOS expressed in stress responses (e.g., SAH)
which contributes to the generation of reactive oxygen species. E2
abrogates SAH-induced iNOS expression by sequestering NF𝜅B, a
transcriptional activator of iNOS.
Endothelin-1 (ET-1) The most potent endogenous mediator of vasoconstriction. E2decreases ET-1 production.
Neuroprotective mechanisms regulated by E2
Thioredoxin (Trx)
Antioxidant enzyme which reduces oxidized proteins and diminishes
stress-induced proapoptotic signaling. E2 increases Trx expression.
c-Jun N-terminal kinase (JNK)
JNK phosphorylates downstream proteins which heterodimerize to
form AP-1, a transcriptional activator of TNF𝛼. E2 decreases JNK
activity.
Neuroglobin (Ngb)
Globin protein which binds to oxygen with a greater affinity than
hemoglobin thereby regulating oxygen homeostasis in neurons. Ngb
provides protection against ROS-induced oxidative damage and
prevents apoptosis by stabilizing the transcription factors HIF-1𝛼 and
Nrf2 and by inhibiting cytochrome c release from the mitochondria.
E2 increases Ngb expression.
Protein kinase B (Akt)
Akt activates mTOR which promotes cell survival and inactivates
GSK3𝛽 which promotes apoptosis. E2 prevents SAH-induced
suppression of Akt.
Adenosine A2a receptor (A2aAR)
G-protein couple receptor which inhibits proapoptotic signaling
pathways partially through activation of ERK 1/2. E2 increases
expression of A2aAR and ERK 1/2.
weeks), we believe the increased risk of estrogen-related
cancers would be negligible. However, the potential systemic
adverse effects of estrogen on patients, especially those with
preexisting medical comorbidities, may be significant. It is
possible that thromboembolic complications associated with
estrogen therapy may offset any benefits afforded by its
vasodilatory or neuroprotectivemechanisms.While estrogen
has been demonstrated to diminish CV and DCI in animal
SAH models, it has yet to be tested in human trials for the
treatment of patients with ruptured aneurysms. Therefore,
the clinical safety profile and efficacy of estrogen have yet
to be determined. Future studies are necessary to establish
a dose-response relationship for estrogen in order to initiate
early phase clinical trials.
7. Conclusions
Estrogen, specifically E2, possesses powerful vasodilatory,
anti-inflammatory, and neuroprotective properties. Its cur-
rent use for the treatment of CV remains limited to in vivo
animal models of experimental SAH. It appears that the
significant majority of E2-mediated neuroprotection occurs
via ER𝛼- and ER𝛽-dependent mechanisms.The contribution
of ER-independent mechanisms of E2 neuroprotection is
relatively small. Therefore, successful pharmacologic modu-
lation of ERs may provide a potential target of future clinical
studies of E2 for the treatment of CV and DCI following
aneurysmal SAH.
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